[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07713901":3,"trial-entities:NCT07713901":73,"trial-summary:NCT07713901":77},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":16,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":34,"secondary_outcomes":39,"sex":40,"minimum_age":41,"maximum_age":16,"healthy_volunteers":14,"eligibility_criteria":42,"std_ages":53,"locations":56,"central_contacts":66,"overall_officials":67,"references":71,"see_also_links":72},"NCT07713901","NN2211-8841","Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma","ENROLLING_BY_INVITATION","2026-12-31","2026-07","2026-07-20","2025-12-31","Novo Nordisk A\u002FS","INDUSTRY",false,"This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.",null,[18],"Medullary Thyroid Carcinoma",[],"OBSERVATIONAL",[],{"count":23,"type":24},93600000,"ESTIMATED",[26],{"type":27,"name":28,"description":28,"armGroupLabels":29},"OTHER","No treatment given",[30,31,32,33],"Long-acting GLP-1 RA Exposed Cohort","Overweight\u002FObesity Active Comparator Cohort","T2D Active Comparator 1 Cohort","T2D Active Comparator 2 Cohort",[35],{"measure":36,"description":37,"timeFrame":38},"Time to first occurence of Medullary Thyroid Carcinoma (MTC)","Measured in number of days.","From day 1 up to 15 years",[],"ALL","18 Years",{"inclusion":43,"exclusion":50,"raw_text":52},[44,45,46,47,48,49],"18 years or older during the year of index (date of qualifying medication)","In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1","≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)","No evidence of cohort qualifying medication during 12-month before the index date","Reside in the US, including the District of Columbia (DC) during the study period","No missing values for year of birth",[51],"Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.","Inclusion Criteria:\n\n* 18 years or older during the year of index (date of qualifying medication)\n* In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1\n* ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period)\n* No evidence of cohort qualifying medication during 12-month before the index date\n* Reside in the US, including the District of Columbia (DC) during the study period\n* No missing values for year of birth\n\nExclusion Criteria:\n\n* Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.",[54,55],"ADULT","OLDER_ADULT",[57],{"facility":58,"city":59,"state":60,"zip":61,"country":62,"geoPoint":63},"IQVIA","Parsippany","New Jersey","07054","United States",{"lat":64,"lon":65},40.85788,-74.42599,[],[68],{"name":69,"affiliation":12,"role":70},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":74,"biomarkers":76},[75],"Thyroid Gland Medullary Carcinoma",[],{"nct_id":4,"found":78,"summary":79,"prompt_version":89},true,{"design":80,"status":81,"heading":82,"summary":83,"follow_up":84,"word_count":85,"commitments":86,"compensation":87,"drugs_mentioned":88},"This is an observational study that uses existing health records and cancer registry data. It is not testing a new treatment and does not involve direct patient participation.","completed","Database Study on Medullary Thyroid Carcinoma Risk","This study is looking at whether certain medicines called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists), used for type 2 diabetes and weight management, might be linked to a rare cancer called medullary thyroid carcinoma (MTC). Researchers will compare how often MTC occurs in people taking these medicines versus those taking other similar treatments. This study uses existing health records and cancer registry data, so no new treatments are given. You could be included if you are 18 or older, have taken certain medications, and meet other criteria related to your prescription history. The main goal is to see how long it takes for MTC to occur, if it does, over a period of up to 15 years. The study is currently unclear on its status and aims to include a very large number of people.","The study will track the time to the first occurrence of Medullary Thyroid Carcinoma (MTC) for up to 15 years.",135,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]